Hanmi Pharmaceutical Company Limited
PharmaSeoul, South Korea, South Korea · Est. 1983 · 1,200 employees
Hanmi Pharmaceutical is a South Korean biopharmaceutical company focused on developing novel drug candidates in oncology and other therapeutic areas.
6
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
185
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
6 drugs in development
Phase 32
Phase 25
By Therapeutic Area
top 1
Metabolic & Endocrine
583%
R&D Momentum
54/100
Pipeline Velocity
27/100
Trial Completion Rate
97/100
Pipeline Concentration
72/100
Pipeline Freshness
28/100
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Recruiting
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus
Jul 8, 2026
Completed
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Jul 7, 2026
Completed
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension
Jul 1, 2026
Active, not recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Earlier
Feb 12, 2026TrialBelvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Feb 1, 2026TrialA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Dec 19, 2025TrialA Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers
Dec 2, 2025TrialStudy to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
3 more events
Nov 6, 2025TrialA Single Ascending Dose Study of HM17321 in Healthy Adult Participants
Dec 11, 2024TrialDose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Nov 22, 2024TrialA Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
Details
Company Info
Company Overview
—
Mkt Cap
$500.0M
Revenue
—
Cash
CEOJae-Ho Choi
Founded1983
Employees1,200
HQSeoul, South Korea, South Korea
Websitehanmipharm.com
LinkedInCompany Page
Therapeutic Focus
OncologyCardiovascularImmunologyNeurology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Unknown / Other
Metabolic & Endocrine
Unknown / Other
Hyperinsulinism
HM15136Phase 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)